Pressroom

Pressroom: Press Releases

2008

Therapeutic Cloning Treats Parkinson's Disease in Mice

Research led by investigators at Memorial Sloan-Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson’s disease in mice.

March 23, 2008
At Home Genomic Tests for Disease Risk Premature

The recent marketing of “at home” genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC).

March 18, 2008
Cardiac Effects Associated with Breast Cancer Treatment Appear Lower with Dose-Dense Delivery of Conventional Chemotherapy

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center found that breast cancer patients can be treated safely with a “dose-dense” regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.

March 6, 2008
Researchers Identify New Genetic Marker for Breast Cancer

An international group of investigators led by scientists at Memorial Sloan-Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.

March 3, 2008
Novel Mechanism Found That May Boost Impaired Function of Leukemia Protein

A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.

February 29, 2008
PSA Testing Can Predict Advanced Prostate Cancer

A single prostate specific antigen (PSA) test taken before the age of 50 can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a new study published by researchers at Memorial Sloan-Kettering Cancer Center in New York and Lund University in Sweden.

February 14, 2008
Benefit of Cancer Prevention Surgery Differs Between Women with BRCA1 and BRCA2 Mutations

The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan-Kettering Cancer Center is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers.

February 11, 2008
Simons Foundation Grant Boosts Brain Tumor Research

A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan-Kettering’s new Brain Tumor Center (BTC).

January 31, 2008
Molecules Can Block Breast Cancer's Ability to Spread

Researchers have identified a specific group of microRNA molecules that are responsible for controlling genes that cause breast cancer metastasis.

January 9, 2008
Breast Cancer Risk Varies Substantially Among Women Who Are Carriers of BRCA1 and BRCA2 Gene Mutations

Breast cancer risk varies widely among women who are carriers of the BRCA1 and BRCA2 mutations, according to a new study published in the January 9, 2008, issue of the Journal of the American Medical Association (JAMA).

January 8, 2008

2007

Cancer Patients May Benefit from Reporting Symptoms Online in Real Time

A new study by researchers at Memorial Sloan-Kettering Cancer Center finds that even the sickest cancer patients are willing and able to “self-report” symptoms using the Internet, thus supplying key data in real time to their healthcare providers.

November 29, 2007
Paul Marks Prize Recognizes Three Young Cancer Researchers

Three young investigators who have made major accomplishments in cancer research will be the recipients of the 2007 Paul Marks Prize for Cancer Research and will share a $150,000 award, announced Memorial Sloan-Kettering Cancer Center (MSKCC).

September 26, 2007
Outcome of Prostate Cancer Surgery Depends on the Experience of the Surgeon

According to a new study published online today in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.

July 24, 2007
Treatment for Early Prostate Cancer Associated with Type of Specialist Seen

A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive.

June 3, 2007
VEGF Trap Shows Activity in Patients with Advanced Ovarian Cancer

Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.

June 2, 2007
Harlem Children Enjoy First Bright Space Center Dedicated Play and Learning Environment

May 23, 2007 NEW YORK - The Bright Horizons Foundation for Children, Memorial Sloan-Kettering Cancer Center (MSKCC), Abyssinian Development Corporation (ADC), and Community Playthings today cut ribbons to officially open Harlem’s first Bright Space center for homeless children at Abyssinian House, a Tier II transitional residence serving the families of Harlem.

May 23, 2007
Iris Cantor Funds Senior Chair at Memorial Sloan-Kettering

philanthropist and art collector Iris Cantor has made a major commitment to Memorial Sloan-Kettering Cancer Center to create an endowed chair for a senior researcher in the field of digestive cancers.

April 18, 2007
Gleevec Decreases Cancer Recurrence for Patients with a Type of Gastrointestinal Cancer

Patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

April 12, 2007
Genes Set Scene for Metastasis

Biologists at Memorial Sloan-Kettering Cancer Center have identified a set of genes expressed in human breast cancer cells that work together to remodel the network of blood vessels at the site of the primary tumor.

April 11, 2007
PET Imaging Identifies Aggressive Kidney Cancers that Require Surgery

A newly published study demonstrates that imaging with Positron Emission Tomography (PET) using a radiolabeled antibody accurately identifies whether a patient has clear cell renal carcinoma - the most common and aggressive type of renal tumor - and arms the urologist with crucial information that will help determine whether surgery is needed.

March 6, 2007
Syndicate content